Evotec AG continued to benefit in 2018 from its dual business model as a service provider and drug discoverer and developer, delivering a 42% increase in revenue to €375 million and a near doubling of operating profit to €77.5 million. One feature of the year was the full integration of the Aptuit contract research organisation, acquired in 2017. Another was a new alliance with Celgene Corp in targeted protein degradation.
